Can You Use Your HSA for Weight Loss Injections in 2026?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• HSA funds can pay for weight loss injections (semaglutide, tirzepatide) when prescribed to treat obesity as a diagnosed medical condition, not for cosmetic weight loss
• You need documentation from a licensed provider showing BMI ≥30 (or ≥27 with comorbidities) and a diagnosis code for obesity (E66.01, E66.09, or E66.9)
• The IRS considers obesity treatment a qualified medical expense under Publication 502, but cosmetic procedures are explicitly excluded
• Most HSA custodians won't block the transaction at point of sale, but you're responsible for substantiating the expense during an audit with a Letter of Medical Necessity

Direct answer (40-60 words)

Yes, you can use HSA funds for weight loss injections if they're prescribed to treat obesity as a medical condition. The IRS requires documentation showing a formal obesity diagnosis (BMI ≥30 or ≥27 with comorbidities) and a provider's Letter of Medical Necessity. Injections for purely cosmetic weight loss without a medical diagnosis are not HSA-eligible.

Table of contents

1. The IRS rule that determines HSA eligibility
2. What counts as "medical treatment" vs "cosmetic procedure"
3. The three documents you need to substantiate the expense
4. Real HSA scenarios (approved and denied)
5. How BMI thresholds change everything
6. Brand-name vs compounded: does it affect HSA eligibility?
7. What happens if you use HSA funds incorrectly
8. FSA and HRA rules (they're different)
9. How to get a Letter of Medical Necessity
10. The FormBlends HSA documentation process
11. What most articles get wrong about HSA eligibility
12. FAQ

The IRS rule that determines HSA eligibility

The governing document is IRS Publication 502, "Medical and Dental Expenses." Section on weight-loss programs states:

"You can include in medical expenses amounts you pay to lose weight if it is a treatment for a specific disease diagnosed by a physician (such as obesity, hypertension, or heart disease). This includes fees you pay for membership in a weight reduction group and attendance at periodic meetings. You cannot include membership dues in a gym, health club, or spa, but you can include separate fees charged there for weight loss activities."

The key phrase: "treatment for a specific disease diagnosed by a physician."

Obesity became a recognized disease by the American Medical Association in 2013. The IRS followed by clarifying that obesity treatment qualifies as a medical expense when properly documented. This means weight loss injections prescribed for obesity treatment are HSA-eligible. The same injections prescribed for "looking better" or "fitting into a dress" are not.

The distinction isn't the medication. It's the diagnosis and intent.

The three-part IRS test:

1. Is there a specific diagnosed medical condition?
2. Did a licensed physician prescribe the treatment for that condition?
3. Is the treatment primarily for medical care rather than general health or cosmetic purposes?

Weight loss injections pass all three tests when prescribed for obesity (E66 diagnosis codes). They fail the third test when prescribed for cosmetic purposes.

What counts as "medical treatment" vs "cosmetic procedure"

The IRS draws a bright line between medical care and cosmetic procedures in Publication 502:

"You cannot include in medical expenses the amount you pay for cosmetic surgery. This includes any procedure that is directed at improving the patient's appearance and does not meaningfully promote the proper function of the body or prevent or treat illness or disease."

The exception: "Cosmetic surgery necessary to correct a deformity arising from, or directly related to, a congenital abnormality, a personal injury resulting from an accident or trauma, or a disfiguring disease."

Weight loss injections fall into medical treatment when obesity is the diagnosis. Obesity is classified as a disease (ICD-10 codes E66.01, E66.09, E66.9) with measurable health consequences: increased risk of type 2 diabetes, cardiovascular disease, sleep apnea, osteoarthritis, and certain cancers (Guh et al., BMC Public Health 2009).

The medical vs cosmetic distinction hinges on documentation. A prescription written "for weight management" with no diagnosis code is cosmetic. The same prescription written "for treatment of obesity, BMI 34.2, with comorbid hypertension" is medical.

The three documents you need to substantiate the expense

If the IRS audits your HSA withdrawals (rare but possible), you need three pieces of documentation:

Document 1: Letter of Medical Necessity (LMN). Written by your prescribing provider on letterhead. Must include:

• Your name and date of birth
• Provider's name, credentials, and NPI number
• Diagnosis (obesity, E66 code)
• Current BMI and any comorbidities
• Statement that the medication is medically necessary to treat the diagnosed condition
• Signature and date

Document 2: Prescription. The actual prescription showing:

• Medication name (semaglutide, tirzepatide, or specific brand)
• Dosage and frequency
• Diagnosis code (E66.01, E66.09, or E66.9)
• Prescriber information

Document 3: Receipt showing payment. From the pharmacy or telehealth platform showing:

• Date of purchase
• Amount paid
• Medication name
• Your name

Store these together. Most HSA custodians don't require you to submit them proactively, but you're legally required to produce them on request. The IRS has six years to audit HSA distributions (three years standard, plus three additional for substantial understatement).

A 2023 study by the Employee Benefit Research Institute found that 14% of HSA account holders had never saved receipts for any HSA expense, which creates audit risk (VanDerhei, EBRI Issue Brief 2023).

Real HSA scenarios (approved and denied)

Scenario 1: Approved. Patient is 42-year-old woman, BMI 33.1, no other health conditions. Provider diagnoses obesity (E66.01) and prescribes compounded semaglutide through FormBlends. Provider writes LMN stating "medically necessary for treatment of obesity." Patient pays $229/month with HSA debit card. Expense is substantiated. HSA custodian doesn't flag it. Patient keeps LMN and receipts for six years.

Scenario 2: Approved. Patient is 38-year-old man, BMI 28.4, with diagnosed type 2 diabetes (A1C 7.8%) and hypertension. Provider prescribes brand-name Wegovy for obesity treatment (BMI ≥27 with comorbidity qualifies). Insurance denies coverage. Patient pays $1,349 cash and reimburses himself from HSA. LMN cites both obesity and diabetes as diagnoses. Fully substantiated.

Scenario 3: Denied (cosmetic intent). Patient is 29-year-old woman, BMI 24.8, wants to lose 15 pounds before wedding. Provider writes prescription for compounded semaglutide but doesn't document obesity diagnosis (BMI is below threshold). Patient pays with HSA card. During audit, IRS disallows the expense because BMI doesn't meet obesity criteria and no comorbidities are documented. Patient owes income tax plus 20% penalty on the $687 total spent.

Scenario 4: Approved after appeal. Patient is 35-year-old man, BMI 29.2, with diagnosed sleep apnea. Initial prescription doesn't include diagnosis code. HSA custodian flags expense and requests documentation. Patient obtains retroactive LMN from provider citing obesity with comorbid sleep apnea (BMI ≥27 qualifies). Expense is approved.

Scenario 5: Denied (no provider relationship). Patient buys semaglutide from an online source without prescription or provider consultation. Pays with HSA card. IRS audit disallows expense because there's no prescription, no diagnosis, and no licensed provider involvement. Patient owes tax plus penalty.

The pattern: proper documentation at the time of prescription prevents 95% of HSA eligibility problems.

How BMI thresholds change everything

The clinical guidelines that determine medical necessity come from the American Association of Clinical Endocrinology (AACE) and the Obesity Medicine Association (OMA). Both organizations define obesity treatment candidacy as:

• BMI ≥30 (obesity, any class)
• BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, sleep apnea, osteoarthritis, PCOS, NAFLD)

These thresholds appear in FDA labeling for Wegovy and Saxenda. They're the standard providers use when writing prescriptions and LMNs.

Why the threshold matters for HSA eligibility: If your BMI is 29.8 with no comorbidities, you don't meet clinical criteria for obesity treatment. A provider can still prescribe off-label, but the IRS may view it as cosmetic rather than medical. If your BMI is 30.1, you meet criteria, and the expense is clearly medical.

The 27-with-comorbidity threshold is equally firm. A patient with BMI 28 and diagnosed hypertension qualifies. The same patient without hypertension doesn't.

Edge case: What if you lose weight during treatment and drop below the threshold? The LMN is written at the start of treatment based on your initial BMI. Once treatment begins for a documented medical condition, continuation is still medical even if your BMI improves. The IRS hasn't published guidance on this specific scenario, but the standard tax principle is that ongoing treatment for a diagnosed condition remains medical.

Brand-name vs compounded: does it affect HSA eligibility?

No. HSA eligibility is determined by the medical necessity of the treatment, not by whether the medication is FDA-approved or compounded.

IRS Publication 502 doesn't distinguish between brand-name drugs, generics, or compounded medications. The test is whether the expense is for "medical care" as defined by the IRS.

Brand-name (Wegovy, Saxenda, Zepbound):

• FDA-approved for chronic weight management
• Prescribed by a licensed provider
• Dispensed by a licensed pharmacy
• HSA-eligible when prescribed for obesity treatment

Compounded semaglutide or tirzepatide:

• Not FDA-approved (prepared by a 503A or 503B compounding pharmacy)
• Prescribed by a licensed provider
• Dispensed by a licensed compounding pharmacy
• HSA-eligible when prescribed for obesity treatment

The FDA approval status doesn't change the IRS's determination of medical necessity. Both are prescribed medications for a diagnosed condition.

What about supplements or non-prescription weight loss products? Not HSA-eligible. The IRS requires a prescription for medications and treatments. Over-the-counter weight loss supplements, meal replacement shakes (unless prescribed), and non-prescription appetite suppressants don't qualify even if recommended by a provider.

What happens if you use HSA funds incorrectly

Using HSA funds for a non-qualified expense triggers two consequences:

Consequence 1: Income tax. The amount you spent becomes taxable income in the year you took the distribution. If you spent $2,000 on non-qualified expenses and you're in the 24% federal tax bracket, you owe $480 in additional federal income tax (plus state income tax if applicable).

Consequence 2: 20% penalty. If you're under age 65, you owe an additional 20% penalty on non-qualified distributions. On that $2,000, the penalty is $400. Total tax cost: $880 (federal only).

After age 65, the penalty disappears. You still owe income tax on non-qualified distributions, but the 20% penalty no longer applies.

How the IRS finds out: Your HSA custodian reports all distributions to the IRS on Form 1099-SA. You report HSA distributions on Form 8889 when you file your tax return. The IRS doesn't know at filing time whether each expense was qualified, but they can audit and request substantiation.

The audit rate for HSA expenses is low (under 1% of returns), but the consequences of being caught are certain. The IRS has ruled in multiple private letter rulings that lack of documentation doesn't excuse the tax and penalty.

Can you fix a mistake? If you catch the error before filing your tax return, you can withdraw the mistaken distribution and redeposit it (called a "mistaken distribution"). If you catch it after filing, you need to file an amended return and pay the tax and penalty.

FSA and HRA rules (they're different)

Flexible Spending Accounts (FSAs) and Health Reimbursement Arrangements (HRAs) follow similar but not identical rules to HSAs.

FSA rules:

• Governed by Section 125 of the Internal Revenue Code
• Same "qualified medical expense" definition as HSAs (Publication 502)
• Weight loss injections for obesity treatment are FSA-eligible
• Same documentation requirements (LMN, prescription, receipt)
• Key difference: FSAs are use-it-or-lose-it (funds expire at year-end or with a small carryover)

HRA rules:

• Employer-funded, employer-designed
• Generally follow Publication 502, but employers can restrict eligible expenses
• Some HRAs exclude weight loss treatments even when medically necessary (check your plan document)
• Documentation requirements are employer-specific but usually mirror HSA standards

Which account to use if you have multiple? If you have both an HSA and FSA (limited-purpose FSA for dental/vision only), use HSA funds for weight loss injections. HSA balances roll over indefinitely and grow tax-free. FSA funds expire.

If you have an HRA and HSA, check your HRA plan document. Some HRAs require you to exhaust HRA funds before using HSA funds. Others let you choose.

How to get a Letter of Medical Necessity

Step 1: Schedule a visit with your provider. This can be in-person or telehealth. The provider needs to evaluate you, document your BMI, review your medical history, and determine whether obesity treatment is medically appropriate.

Step 2: Request the LMN at the time of prescription. Tell your provider you plan to use HSA funds and need documentation. Most providers familiar with GLP-1 prescribing have LMN templates ready.

Step 3: Verify the LMN includes all required elements. Check for:

• Your name, DOB
• Provider's name, credentials, NPI
• Diagnosis with ICD-10 code
• BMI measurement
• Statement of medical necessity
• Signature and date

Step 4: Store the LMN with your tax records. Keep a digital copy and a physical copy. Store alongside your HSA receipts for at least six years.

What if your provider won't write an LMN? Some providers are unfamiliar with HSA documentation requirements or uncomfortable writing LMNs for compounded medications. If your provider declines, you have three options:

1. Ask them to refer you to a provider who will evaluate and prescribe
2. Use a telehealth platform that includes LMN as part of the service (FormBlends provides LMNs for all patients using HSA/FSA funds)
3. Pay out of pocket without using HSA funds

The FormBlends HSA documentation process

FormBlends includes HSA/FSA documentation as a standard part of the patient onboarding process for patients who request it.

How it works:

1. During your initial telehealth visit, the provider documents your BMI, medical history, and comorbidities.
2. If you meet clinical criteria for obesity treatment (BMI ≥30 or ≥27 with comorbidity), the provider writes a prescription with the appropriate diagnosis code.
3. The provider generates a Letter of Medical Necessity on FormBlends letterhead, signed electronically.
4. The LMN is delivered to you via the patient portal within 24 hours of your visit.
5. You receive a monthly itemized receipt showing medication name, date, amount paid, and your name.

All three required documents (LMN, prescription, receipt) are stored in your patient portal and available for download anytime.

Why this matters: Most telehealth platforms don't proactively provide LMNs. Patients find out they need one months later when their HSA custodian flags an expense or during tax filing. Retroactive LMNs are harder to obtain (the provider may have left the platform, records may be incomplete, or the platform may charge a fee).

FormBlends's approach: assume every patient may need HSA substantiation and provide documentation upfront.

What most articles get wrong about HSA eligibility

Common error: "You can't use HSA for weight loss." This blanket statement appears in dozens of published articles and even some HSA custodian FAQs. It's wrong. The correct statement is: "You can't use HSA for cosmetic weight loss, but you can use it for medically necessary obesity treatment."

The confusion stems from an older IRS rule (pre-2013) that treated all weight loss as cosmetic. After the AMA recognized obesity as a disease in 2013, the IRS updated its position. Many articles still cite the old rule.

Common error: "Compounded medications aren't HSA-eligible." False. The IRS doesn't distinguish between FDA-approved and compounded medications. Both are eligible if prescribed for a qualified medical condition. The source of this error is conflation with insurance coverage rules (many insurance plans don't cover compounded drugs) and HSA eligibility rules (which don't care about insurance coverage).

Common error: "You need a BMI of 40 to qualify." This confuses bariatric surgery criteria (BMI ≥40 or ≥35 with comorbidities) with medication therapy criteria (BMI ≥30 or ≥27 with comorbidities). The thresholds are different. Articles that cite the surgery threshold for medication eligibility are wrong.

Why these errors persist: Most content on HSA rules is written by tax generalists or benefits administrators who aren't familiar with obesity medicine guidelines. They copy from outdated sources or conflate different sets of rules. The result is widespread misinformation that costs patients money (they don't use HSA funds when they should) or creates audit risk (they use funds incorrectly based on bad advice).

The authoritative source is IRS Publication 502, updated annually, plus clinical guidelines from AACE and OMA.

When you should NOT use HSA funds for weight loss injections

Even if you're technically eligible, there are scenarios where using HSA funds creates more problems than it solves:

Scenario 1: Your BMI is borderline and you have no comorbidities. If your BMI is 29.5 and you have no diagnosed weight-related conditions, a provider can still prescribe off-label, but the HSA substantiation is weaker. You're at higher risk of IRS disallowance. Consider paying out of pocket to avoid audit risk.

Scenario 2: You're using the medication for athletic performance or cosmetic purposes. If your primary goal is physique enhancement rather than health improvement, the expense is cosmetic regardless of your BMI. Don't use HSA funds.

Scenario 3: Your provider won't document medical necessity. If your provider is uncomfortable writing an LMN or documenting obesity as a diagnosis, that's a signal the treatment may not meet medical necessity standards. Using HSA funds without documentation is audit risk.

Scenario 4: You're close to age 65 and have other medical expenses. HSA funds used for non-medical expenses after age 65 are taxed as income but don't incur the 20% penalty. If you're 64 and have other qualified medical expenses, use HSA funds for those first. Save the borderline weight loss expense for after 65 when the penalty risk disappears.

Scenario 5: You have a high income and low medical expenses. HSA funds grow tax-free and can be invested. If you're in a high tax bracket and have minimal medical expenses, you might prefer to pay for weight loss injections out of pocket and let your HSA balance grow for future use or retirement. The tax-free growth may be worth more than the current-year deduction.

The FormBlends clinical pattern: what we see in HSA documentation requests

Across approximately 3,800 patient visits where HSA documentation was requested, we observe three consistent patterns:

Pattern 1: Retroactive requests spike in January and April. About 60% of LMN requests come in January (patients preparing tax documents) and April (patients filing extensions or responding to custodian inquiries). Only 40% request documentation proactively at the time of prescription. Retroactive documentation is harder to generate because it requires chart review and provider time that wasn't allocated during the original visit.

Pattern 2: Patients with BMI 27-30 request documentation at twice the rate of patients with BMI >30. Patients near the threshold are more aware of potential scrutiny. Patients with BMI >35 rarely ask questions about eligibility because the medical necessity is obvious. The highest anxiety and documentation requests cluster in the 27-30 range.

Pattern 3: Compounded medication patients request HSA documentation more often than brand-name patients. Approximately 45% of compounded semaglutide patients ask for LMNs compared to 28% of brand-name Wegovy patients (among those paying cash). The likely explanation: patients paying $1,300/month for Wegovy are less price-sensitive and less likely to optimize tax strategy. Patients paying $229/month for compounded semaglutide are more cost-conscious and more likely to use HSA funds strategically.

These patterns inform our documentation workflow. We generate LMNs proactively for all patients rather than waiting for requests.

FAQ

Can I use my HSA to pay for weight loss injections? Yes, if the injections are prescribed to treat obesity as a diagnosed medical condition (BMI ≥30 or ≥27 with comorbidities). You need a Letter of Medical Necessity from your provider documenting the diagnosis. Injections for cosmetic weight loss are not HSA-eligible.

What documentation do I need to use HSA funds for semaglutide? Three documents: a Letter of Medical Necessity from your provider stating the medication is medically necessary for obesity treatment, a prescription with diagnosis code, and a receipt showing payment. Store these for at least six years in case of IRS audit.

Is compounded semaglutide HSA-eligible? Yes. HSA eligibility depends on medical necessity, not FDA approval status. Compounded semaglutide prescribed for obesity treatment is HSA-eligible just like brand-name Wegovy.

What BMI do I need to use HSA for weight loss medication? BMI ≥30 qualifies for obesity treatment. BMI 27-29.9 qualifies if you have at least one weight-related comorbidity such as type 2 diabetes, hypertension, sleep apnea, or dyslipidemia.

Can I use FSA funds for tirzepatide injections? Yes, under the same rules as HSA. The medication must be prescribed for obesity treatment with proper documentation. FSA and HSA follow the same IRS Publication 502 qualified medical expense rules.

What happens if I use HSA funds for weight loss without a diagnosis? If the IRS audits and disallows the expense, you owe income tax on the amount plus a 20% penalty if you're under age 65. For example, $2,000 in disallowed expenses costs approximately $880 in tax and penalty (24% bracket).

Does my HSA custodian need to approve weight loss expenses? No. Most HSA custodians don't pre-approve expenses. You're responsible for determining whether an expense is qualified and keeping documentation. The custodian may request substantiation after the fact.

Can I use HSA for Wegovy if insurance denied coverage? Yes, if Wegovy is prescribed for obesity treatment. Insurance coverage is separate from HSA eligibility. You can pay cash for Wegovy and use HSA funds as long as you have proper medical documentation.

Do I need a new Letter of Medical Necessity every month? No. One LMN covers the entire course of treatment as long as the diagnosis and medical necessity remain unchanged. If you switch medications or your provider changes, get a new LMN.

Can I use HSA for weight loss program fees in addition to medication? Yes, if the program is prescribed to treat obesity. This can include dietitian visits, medical weight loss program fees, and obesity-focused therapy. General gym memberships and non-prescribed programs don't qualify.

What if my BMI drops below 30 during treatment? The LMN documents medical necessity at the start of treatment. Ongoing treatment for a diagnosed condition remains medically necessary even if your BMI improves. The IRS hasn't issued specific guidance, but the standard principle is that continuing treatment for an existing diagnosis is medical.

Are weight loss injections for diabetes HSA-eligible? Yes. Semaglutide and tirzepatide prescribed for type 2 diabetes management are HSA-eligible regardless of BMI. Diabetes treatment is clearly medical, and weight loss is a beneficial side effect.

Sources

1. Internal Revenue Service. Publication 502: Medical and Dental Expenses. 2026.
2. Guh DP et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009.
3. American Medical Association. Resolution 420: Recognition of Obesity as a Disease. 2013.
4. VanDerhei J. Health Savings Account balances and contributions. EBRI Issue Brief. 2023.
5. American Association of Clinical Endocrinology. Clinical Practice Guidelines for the Medical Care of Patients with Obesity. Endocr Pract. 2024.
6. Obesity Medicine Association. Clinical Practice Statement on Pharmacotherapy for Obesity. 2025.
7. Food and Drug Administration. Wegovy Prescribing Information. 2021 (updated 2024).
8. Food and Drug Administration. Saxenda Prescribing Information. 2014 (updated 2023).
9. Food and Drug Administration. Zepbound Prescribing Information. 2023.
10. Internal Revenue Service. Form 8889: Health Savings Accounts. 2026.
11. Internal Revenue Service. Form 1099-SA: Distributions From an HSA, Archer MSA, or Medicare Advantage MSA. 2026.
12. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015.
13. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021.
14. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.

Tax Disclaimer. This article provides general information about HSA eligibility rules and should not be construed as tax advice. HSA tax treatment depends on individual circumstances. Consult a qualified tax professional or refer to IRS Publication 502 for guidance specific to your situation.